title: 6-Keto-prostaglandin E1 is more potent than prostaglandin I2 as a renal vasodilator and renin secretagogue.
abstract: Several studies indicate that prostaglandin (PG) I2 is involved in the control of renin release. This investigation was performed to determine if the active possible metabolite of PGI2, 6-keto-PGE1, is also a renin secretagogue. The relative potencies of PGI2, 6-keto-PGE1 and 6-keto-PGF1 alpha on renin secretion rate (RSR) and renal blood flow (RBF) were assessed in nonfiltering, beta adrenoreceptor blocked kidneys of seven anesthetized dogs. Intrarenal infusions of both PGI2 and 6-keto-PGE1 significantly augmented RSR in a dose-related fashion. However, 6-keto-PGE1 was approximately 5 times more potent than PGI2, producing significantly greater increases in RSR at doses from 3 X 10(-9) to 3 X 10(-8 g/kg/min (P < .03). At low infusion rates (less than 3 X 10(-8) g/kg/min), 6-keto-PGE1 enhanced RBF to a greater extent than PGI2. However, with infusion rates of 3 X 10(-8) g/kg/min, these eicosanoides enhanced RBF to an equal extent. Thus, in comparison to PGI2, 6-keto-PGF1 induced a greater increase in RSR for equivalent increases in RBF. 6-keto-PGF 1 alpha had no effect on either RSR or RBF at any of the doses infused. We conclude that, in the canine kidney, 6-keto-PGE1 is more potent than PGI2 in stimulating the juxtaglomerular cells to secrete renin.
mesh_terms: D000527:Alprostadil / Q000031:analogs & derivatives*; D000818:Animals; D004285:Dogs; D011464:Epoprostenol / Q000494:pharmacology*; D005260:Female; D066298:In Vitro Techniques; D007668:Kidney / Q000098:blood supply*; D008297:Male; D011453:Prostaglandins / Q000494:pharmacology*; D011458:Prostaglandins E / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D012083:Renin / Q000378:metabolism*; D014665:Vasodilator Agents
chemical_list: D011453:Prostaglandins; D011458:Prostaglandins E; D014665:Vasodilator Agents; C022950:6-ketoprostaglandin E1; D011464:Epoprostenol; D012083:Renin; D000527:Alprostadil